World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
124
Citations
67082
World Ranking
3189
National Ranking
1763

Robert G. Maki publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert G. Maki sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 498 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert G. Maki D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert G. Maki sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 124 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert G. Maki is affiliated with the University of Pennsylvania in the United States. Their research primarily centers on medicine, with a focus on several subfields including pulmonary and respiratory medicine, oncology, pathology and forensic medicine, cardiology and cardiovascular medicine, and rheumatology.

The main topics of Robert G. Maki's work include sarcoma diagnosis and treatment, vascular tumors and angiosarcomas, cardiac tumors and thrombi, cancer genomics and diagnostics, lymphoma diagnosis and treatment, gastrointestinal tumor research and treatment, and cancer immunotherapy and biomarkers.

Robert G. Maki has contributed to multiple recent papers, notably:

  • "A framework for advancing our understanding of cancer-associated fibroblasts," 2020, Nature Reviews. Cancer
  • "The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients," 2020, European Journal of Cancer
  • "Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas," 2020, OncoImmunology
  • "Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology," 2020, Journal of Clinical Oncology
  • "Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma," 2022, Nature Communications

Frequent co-authors collaborating with Robert G. Maki include William D. Tap, Mrinal M. Gounder, Sandra P. D'Angelo, Cristina R. Antonescu, and Silvia Stacchiotti. These partnerships have contributed to a substantial body of work in the field.

Robert G. Maki's publications appear regularly in several venues, with the most frequent venues being the Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, The Oncologist, and Cancer Research.

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • A framework for advancing our understanding of cancer-associated fibroblasts

    Erik Sahai;Igor Astsaturov;Edna Cukierman;David G. DeNardo

  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

    Ronald P. DeMatteo;Karla V. Ballman;Cristina R. Antonescu;Robert G. Maki

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

    George D. Demetri;Margaret Von Mehren;Cristina R. Antonescu;Ronald P. DeMatteo

  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

    Hussein A Tawbi;Melissa Burgess;Vanessa Bolejack;Brian A Van Tine

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas

    Adam Abeshouse;Clement Adebamowo;Sally N. Adebamowo;Rehan Akbani

  • Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

    Cristina R. Antonescu;Peter Besmer;Tianhua Guo;Knarik Arkun

  • Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Robert G. Maki;Christopher L. Corless;Cristina R. Antonescu

  • Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

    James E. Butrynski;David R. D’Adamo;Jason L. Hornick;Paola Dal Cin

  • Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas

    Robert G. Maki;J. Kyle Wathen;Shreyaskumar R. Patel;Dennis A. Priebat

  • Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

    George D. Demetri;Margaret von Mehren;Robin L. Jones;Martee L. Hensley

  • Quantitative analysis of cytokine gene expression in rheumatoid arthritis.

    GS Firestein;JM Alvaro-Gracia;R Maki

  • Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

    Martee L. Hensley;Robert Maki;E. Venkatraman;Gennifer Geller

  • Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

    Jordi Barretina;Barry S Taylor;Barry S Taylor;Shantanu Banerji;Shantanu Banerji;Alexis H Ramos;Alexis H Ramos

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

Frequent Co-Authors

Cristina R. Antonescu
Cristina R. Antonescu Memorial Sloan Kettering Cancer Center
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Murray F. Brennan
Murray F. Brennan Memorial Sloan Kettering Cancer Center
Samuel Singer
Samuel Singer Memorial Sloan Kettering Cancer Center
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Ronald P. DeMatteo
Ronald P. DeMatteo University of Pennsylvania
Shreyaskumar Patel
Shreyaskumar Patel The University of Texas MD Anderson Cancer Center
Margaret von Mehren
Margaret von Mehren Fox Chase Cancer Center
Antoine Italiano
Antoine Italiano University of Bordeaux
Gary K. Schwartz
Gary K. Schwartz Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA doesn't always mean attending traditional, in-person medical school. Many related health fields offer flexible, affordable online degree pathways that can help you enter the healthcare industry or advance your career.

For example, aspiring pharmacists might explore the cheapest online pharmacy school options for earning a doctoral degree with less student debt. If you are interested in using technology to improve patient care, you can consider a degree in health informatics, where demand continues to rise.

Those curious about the administrative side of healthcare can look into certificate programs and associate degrees in medical coding and billing. The average cost of medical billing and coding program is notably lower than many other healthcare credentials, making it a cost-effective entry point.

For nurses aiming to take their careers further, various online nurse practitioner programs allow you to advance your qualifications and clinical skills without leaving your job. Whether you want to work directly with patients or manage health information, online programs offer flexibility, affordability, and access to growing healthcare careers.

Best Scientists Citing Robert G. Maki

Trending Scientists

Recently Published Articles